Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.62, marking a -1.16% move from the previous day....…
19,050€
2,42%
Echtzeit-Aktienkurs Syndax Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Syndax Pharmaceuticals Inc. Aktie
Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline…
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article....…
Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?
Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year....…
Form 8-K Syndax Pharmaceuticals For: Dec 14
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Kura Oncology falls Syndax gains after Phase 1/2 data for leukemia candidates
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute…
Form 8-K Syndax Pharmaceuticals For: Dec 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax Pharmaceuticals Shares Drop 11% After Public Offering Prices
Syndax Pharmaceuticals Shares Drop 11% After Public Offering Prices...…
Syndax Pharmaceuticals prices $150m offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax Announces Pricing of $150 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical…
Syndax Pharma to sell $150M stock in public offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax Announces Proposed $150 million Public Offering of Common Stock
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical…
Syndax receives breakthrough therapy tag for revumenib to treat acute leukemia
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Syndax Gets FDA Breakthrough Designation for Revumenib in KMT2Ar Leukemia >SNDX
Syndax Gets FDA Breakthrough Designation for Revumenib in KMT2Ar Leukemia >SNDX...…
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
-- Revumenib is the first and only investigational treatment for R/R KMT2Ar acute leukemia to receive Breakthrough Therapy Designation --…
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
– Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all patients; and an ORR of…
Insiderhandel: Chief Scientific Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 195.089$
Ordentlich, Peter - Vorstand - Tag der Transaktion: 2022-12-01...…
Insiderhandel: Chief Scientific Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 430.936$
Ordentlich, Peter - Vorstand - Tag der Transaktion: 2022-12-02...…
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
WALTHAM, Mass., Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline…
Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 39.1% upside potential for Syndax (SNDX). While empirical research shows that this sought-after…
Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline…
Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 774.412$
Katkin, Keith - Aufsichtsrat - Tag der Transaktion: 2022-10-06...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 410.508$
Metzger, Michael A. - Vorstand - Tag der Transaktion: 2022-10-06...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 4.500$
Katkin, Keith - Aufsichtsrat - Tag der Transaktion: 2022-10-03...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 740.757$
Metzger, Michael A. - Vorstand - Tag der Transaktion: 2022-09-30...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 9.000$
Katkin, Keith - Aufsichtsrat - Tag der Transaktion: 2022-10-04...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 89.277$
Katkin, Keith - Aufsichtsrat - Tag der Transaktion: 2022-09-30...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 32.026$
Metzger, Michael A. - Vorstand - Tag der Transaktion: 2022-10-04...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 72.107$
Metzger, Michael A. - Vorstand - Tag der Transaktion: 2022-10-03...…